Open AccessEfficacy of abiraterone acetate for high-risk hormone-naïve metastatic prostate cancer: A comparison with combined androgen blockade therapy with bicalutamide and androgen deprivation therapy alone
Author(s) -
Kent Kanao,
Takayuki Takahashi,
Yuta Umezawa,
Takashi Okabe,
Go Kaneko,
Suguru Shirotake,
Koshiro Nishimoto,
Masafumi Oyama
Publication year - 2022
Publication title -
plos one
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.99
H-Index - 332
ISSN - 1932-6203
DOI - 10.1371/journal.pone.0276081
Subject(s) - bicalutamide , medicine , prostate cancer , androgen deprivation therapy , propensity score matching , abiraterone acetate , hazard ratio , antiandrogen , urology , oncology , androgen , prostate specific antigen , confidence interval , hormone therapy , blockade , androgen receptor , hormone , cancer , breast cancer , receptor
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom